These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21738898)

  • 1. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus.
    Kim SA; Shim WH; Lee EH; Lee YM; Beom SH; Kim ES; Yoo JS; Nam JS; Cho MH; Park JS; Ahn CW; Kim KR
    Diabetes Metab J; 2011 Apr; 35(2):159-65. PubMed ID: 21738898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
    Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
    Gagliardino JJ; Santoro S; Arellano S; Di Girolamo G
    Expert Opin Pharmacother; 2008 Jun; 9(9):1495-507. PubMed ID: 18518780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus.
    Chung HS; Lee MK
    Diabetes Metab J; 2011 Aug; 35(4):411-7. PubMed ID: 21977462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.
    Vardarli I; Arndt E; Deacon CF; Holst JJ; Nauck MA
    Diabetes; 2014 Feb; 63(2):663-74. PubMed ID: 24186866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
    Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
    Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus.
    Yang HK; Kang B; Lee SH; Kim HS; Yoon KH; Cha BY; Cho JH
    Diabetes Metab J; 2015 Aug; 39(4):335-41. PubMed ID: 26301196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes.
    da Silva GM; Nogueira KC; Fukui RT; Correia MR; Dos Santos RF; da Silva ME
    Curr Pharm Des; 2016; 22(44):6716-6721. PubMed ID: 27928958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin.
    Chung HS; Suh S; Kim MY; Kim SK; Kim HK; Lee JI; Hur KY; Kim JH; Min YK; Lee MS; Kim KW; Kim SW; Chung JH; Lee MK
    J Diabetes Investig; 2014 Feb; 5(1):51-9. PubMed ID: 24843737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin.
    Kim YA; Yoo WS; Hong ES; Ku EJ; Park KS; Lim S; Cho YM; Park KS; Jang HC; Choi SH
    Diabetes Metab J; 2015 Dec; 39(6):489-97. PubMed ID: 26616595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study.
    Nogueira KC; Furtado M; Fukui RT; Correia MR; Dos Santos RF; Andrade JL; Rossi da Silva ME
    Diabetol Metab Syndr; 2014; 6(1):103. PubMed ID: 25285158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1.
    Kushiyama A; Kikuchi T; Tanaka K; Tahara T; Takao T; Onishi Y; Yoshida Y; Kawazu S; Iwamoto Y
    World J Diabetes; 2016 Jun; 7(11):230-8. PubMed ID: 27326345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.